Dr. Michael Schönhofen, head of Fresenius Kabi’s Biopharma business, will leave the company on June 30, 2024, after over 30 successful years. His successor, Dr. Sang-Jin Pak, will join the Fresenius Kabi Management Board on June 1, 2024, ensuring a smooth transition.
Michael Sen, Fresenius CEO and Chairman of the Fresenius Kabi Supervisory Board, praised Biopharma’s recent achievements, including the launch of the biosimilar Tyenne for treating inflammatory and autoimmune diseases in the EU and USA. He expressed gratitude to Dr. Schönhofen for his tireless dedication and excellent work, wishing him well for the future. Sen also welcomed Dr. Pak, highlighting his extensive international management experience and expertise in biopharma, which will drive further innovation and growth for the company.
Pierluigi Antonelli, Fresenius Kabi CEO and member of the Fresenius Management Board, acknowledged Dr. Schönhofen’s significant contributions to expanding the Biopharma business into a major growth platform for the company. He emphasized that the seamless leadership transition will maintain the momentum and innovative strength of the Biopharma platform.
Dr. Michael Schönhofen began his career in 1991 as head of the dialyzers business unit at Fresenius Medical Care. His roles included working in St. Wendel, Germany, and Ogden, Utah, USA, and overseeing the disposables business unit for Europe, Asia, the Middle East, and Latin America. He has been a member of the Fresenius Kabi Management Board since 2004.
Dr. Sang-Jin Pak, who will be based in Bad Homburg, Germany, joins Fresenius Kabi from Samsung Bioepis, where he has served as Executive Vice President of the Global Commercial business unit since 2018. His previous roles include leading GlaxoSmithKline’s German business and serving as Managing Director of AstraZeneca in Korea. Dr. Pak studied medicine at Johannes Gutenberg University Mainz and healthcare management at the universities of Mannheim and Heidelberg.
